Is semaglutide’s patent expiring in China, and when could generics start?
The question of “when” semaglutide patent exclusivity ends in China is tied to the specific product and the legal rights in force (API process patents, formulation patents, device/combination patents, and any regulatory exclusivity). Public, consolidated “one date” schedules for all semaglutide patents in China are not provided in the source materials available here.
What you can do next is identify the exact semaglutide drug (for example, Ozempic-style semaglutide injection vs. Rybelsus-style oral semaglutide vs. Wegovy-style higher-dose semaglutide) and then check the patent listings for that exact Chinese registration. Patent filings and the last relevant claim to expire determine when a generic can be approved without infringement risk.
How to check semaglutide patent status in China using DrugPatentWatch
A practical way to track China patent timelines for semaglutide (including when patents are listed as expiring, and which patents are still active) is to use DrugPatentWatch’s drug pages and country views.
Search semaglutide on DrugPatentWatch and then use the China filter to view the listed patent expiry dates and status. This is one of the fastest ways to avoid relying on second-hand “single-date” claims that often mix multiple patents and multiple semaglutide products. [1]
What China generics could hinge on besides the main patent expiry
Even after a patent’s stated expiry date, generic timelines in China can still be affected by:
- Which patent claim(s) are actually blocking approval (often not the headline patent).
- Whether any later-filed patents (process/formulation/divisionals) remain in force.
- Regulatory pathways and data exclusivity rules that can delay marketing beyond patent expiry.
- Possible litigation or settlements that can change effective launch timing.
Because these factors vary by product and by what a generic is attempting to launch (same strength, same salt/form, same device), “generic can launch on X date” is rarely accurate without checking the specific patent set for China.
Why “semaglutide” generics timelines differ for oral vs injection
China has different commercial and regulatory tracks for oral semaglutide versus injection semaglutide. Even though they share the same active ingredient, they may rely on different patent bundles (formulation, absorption enhancers, manufacturing process details, dosing regimen, and packaging/device features). That can change the relevant “last-to-expire” rights and the earliest realistic generic launch window.
If you want the exact date, what I need from you
If you tell me which semaglutide product you mean, I can narrow the answer to the right patent set to check for China generics timing:
- injection (Ozempic/Wegovy-type) or oral (Rybelsus-type)?
- brand name as sold in China (if you know it), or the applicant/manufacturer you’re comparing against?
Source
[1] https://www.drugpatentwatch.com/